[Aminopyridines for symptomatic treatment of multiple sclerosis].

Abstract

3,4-diaminopyridine (DAP) and 4-aminopyridine (AP) block potassium channels and can improve action potentials in demyelinated nerve fibres. We identified ten randomised placebo-controlled trials investigating AP/DAP as symptomatic treatment in multiple sclerosis. There is evidence that AP and DAP improve muscle strength in the lower extremities and that AP increases walking speed, and it might improve Expanded Disability Status Scale scores, spasticity and fatigue. There is a lack of evidence-based guidelines of treatment and studies investigating the effect on participation/activity and quality of life.

• Authors: Henrik Boye Jensen, Egon Stenager, Mads Henrik Ravnborg
• Journal: Ugeskrift for laeger (Ugeskr Laeger) Vol. 173 Issue 50 Pg. 3259-63 (Dec 12 2011) ISSN: 1603-6824 [Electronic] Denmark
• Vernacular Title: Aminopyridiner til symptomatisk behandling af multipel sklerose.
• PMID: 22153210 (Publication Type: Journal Article)

Chemical References

• Potassium Channel Blockers
• 4-Aminopyridine
• Amifampridine

Topics

• 4-Aminopyridine (adverse effects, analogs & derivatives, therapeutic use)
• Action Potentials (drug effects)
• Amifampridine
• Evidence-Based Medicine
• Humans
• Lower Extremity (physiopathology)
• Multiple Sclerosis (diagnosis, drug therapy, physiopathology)
• Muscle Strength (drug effects)
• Potassium Channel Blockers (adverse effects, therapeutic use)
• Walking (physiology)